Michael Nall, Biocept's President and CEO, added, "We are very proud to be working with VWR, for the distribution of our proprietary liquid biopsy collection tubes. 2 Million Registered Direct Offering Biocept, Inc. 44 percent to $1. Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc. The MarketWatch News Department was not involved in the creation of this content. Hale, 70 Non-Executive Chairman, Biocept, Inc. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. Please don't submit any personal information. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Biocept, Inc. View company web site for more details. 5810 Nancy Ridge Dr. (NASDAQ:BIOC), a leading. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences technology companies. Biocept expands uses for its Target Selector liquid biopsy tech, expands Biocept Inc (NASDAQ: BIOC) CEO Mike Nall tells Proactive the molecular diagnostics company, is expanding uses for its flagship liquid biopsy Target Selector technology which detects cancer biomarkers. The BIO CEO and Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. (BIOC) Michael W. NAPOLITAN RAYMOND S JR (Executive Vice President) sold 8,000 shares at $52. About Biocept Biocept, Inc. SAN DIEGO, June 25, 2018 /PRNewswire/ -- Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Board of Directors of Biocept Inc. Nall has issued the following letter to stockholders:. Shares of Biocept Inc (NASDAQ: biomarker assay or a larger NGS-based liquid biopsy test panel for use when more comprehensive testing is desired," CEO Michael Nall said in a statement. Jody Cain - LHA, IR. The following slide deck was published by Biocept, Inc. , the largest health insurer in Iowa and South Dakota. View the real-time BIOC price chart on Robinhood and decide if you want to buy or sell commission-free. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to. Biocept expands uses for its Target Selector liquid biopsy tech, expands Biocept Inc (NASDAQ: BIOC) CEO Mike Nall tells Proactive the molecular diagnostics company, is expanding uses for its flagship liquid biopsy Target Selector technology which detects cancer biomarkers. If you're checking for Biocept Inc email addresses, these are also available on Lead411 with the @biocept. Registration Statement on Form S-1 Filed November 4, 2019 File No. (NASDAQ: BIOC), a leading commercial. 02% gain, an insight into the fundamental values of Biocept, Inc. Biocept, Inc. By continuing to use our service, you agree to our use of cookies. The conference call can be accessed by dialing (855) 656-0927 for domestic. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information. Guidelines. com - March 18 at 6:22 PM Biocept, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Diagnostics Oncology Personnel News Release - February 14, 2020 Biocept Appoints Cory J. Biocept is a local molecular diagnostics company developing liquid biopsies to improve the detection and treatment of cancer. com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Mike Nall, CEO of Biocept, Inc. Please don't submit any personal information. Biocept Inc (BIOC) Biocept Inc is a healthcare company that uses liquid biopsy technology to assess several forms of cancer for physicians. com Facebook View on Facebook LinkedIn View on LinkedIn Twitter View on Twitter Contact Email [email protected] B Units,and other labs equipments. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA. Biocept, Inc. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. 76% Jan-14-20 08:05AM Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid PR Newswire +14. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. Tim Kennedy - SVP. They also assigned headlines about the medical research company a news buzz of 0. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. 1 Wall Street analysts have issued ratings and price targets for Biocept in the last 12 months. Their average twelve-month price target is $1. Please wait while we load your information from QuoteMedia. 8 on InfoTrie's scale. Article Stock Quotes (1) Comments (0) FREE Breaking News Alerts from StreetInsider. This analysis aims first to contrast CEO compensation. Biocept, Inc. BIO CEO & Investor Conference Feb 8-9, 2021 New York, New York. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript Seeking Alpha Nov 13, 2019 Biocept EPS beats by $0. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and. SAN DIEGO, Nov. LOS ANGELES, CA / ACCESSWIRE / March 18, 2020 / StockNewsNow. It is worth noting that the CEO compensation consists almost entirely of the salary, worth US$426k. SAN DIEGO, Feb. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. 53M shares in trading volumes in the last trading session, way higher than the average trading volume of 15. 18, 2017 /PRNewswire/ -- Biocept, Inc. Biocept Reports 2019 Fourth Quarter and Full Year Financial Results - Fourth quarter revenues reached a record $1. Is Biocept, Inc. 5% as of 11:41 a. Late last week, just before the holiday weekend, the diagnostics company said that it would begin COVID-19 testing. Biocept Appoints Michael Nall as CEO SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. ET on Seeking Alpha Biocept (BIOC) Receives a Buy from Maxim Group. Biocept, Inc. (NASDAQ: BIOC) soared 56. Based in Vancouver, British Columbia, the pre-clinical stage biopharmaceutical company specializes in developing novel therapies through the research and development into the extensive. Company Website. com - 14 - Shares of Biocept Inc. > Biocept is changing the way physicians examine blood work for their cancer patients COVID-19 Coronavirus Outbreak – Latest Media Coverage Biocept is changing the way physicians examine blood work for their cancer patients. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Goldberg was a partner at Mohr Davidow Ventures, a venture capital firm, where he led life sciences investments in the area of molecular diagnostics, personalized medicine, and wireless healthcare. "Our new dual sample kit offers researchers and assay developers. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Over 20,000 CEO, Equity Analyst and Money Manager Interviews Subscribe now!. and Oasis Biosciences, Inc. , a Chairman at Recros Medica, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and 12 months ended December 31, 2019, and provides an update on its business progress. Ask a question. (BIOC) is based in the USA and it represents one of the well-known company operating with Healthcare sector. 46,233 people own Biocept on Robinhood on May 6, 2020. Biocept (BIOC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Hale was appointed Executive Chairman of Biocept in March 2011. 8 million, up 108% over the fourth quarter of 2018 and up 17% over the third. The Wall Street Transcript is a completely unique resource for investors and business researchers. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. SAN DIEGO, Feb. Wainwright Global. A free inside look at company reviews and salaries posted anonymously by employees. General Public Ownership. More Recent News About Biocept Inc. Coutts, who was named as Biocept’s CEO in 2008, told me he had just lost a daughter to cancer, and he convinced the board that cancer diagnostics was the best use of Biocept’s technology. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. SAN DIEGO, June 25, 2018 /PRNewswire/ -- Biocept, Inc. 2 million in cash as of March 31, 2018. A seasoned veteran in the molecular diagnostics and liquid biopsy industries, Mr. Salaries posted anonymously by Biocept employees. See Michael W Nall's compensation, career history, education, & memberships. What is the work environment and culture like?. It is worth noting that the CEO compensation consists almost entirely of the salary, worth US$426k. 46,233 people own Biocept on Robinhood on May 6, 2020. (NASDAQ:BIOC) Q4 2018 Results Earnings Conference Call March 28, 2019 4:30 PM ET Company Participants. Our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. Its revenue is down -36% over last year. Nall President and Chief Executive Officer About Biocept Biocept, Inc. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday. 7, 2019 /PRNewswire/ -- Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. Your question will be posted publicly. 67 %, while year-to-date (YTD) performance is 34. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference. [ May 4, 2020 ] US FDA Allows Trial to Proceed for Alume Biosciences’ Nerve Imaging Candidate News [ May 4, 2020 ] Nitto BioPharma Inc. (BIOC) on CEO. Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. President and Chief Executive Officer. 00 per share. Biocept, Inc. com email addresses and possibly Michael Nall's email. Daily Earnings Calls 16 views. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecula. via Skype, and they discuss the following topics:. Biocept Inc (NASDAQ: BIOC) CEO Mike Nall says the San Diego-based biotech firm delivered revenue of $1. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information. Arnold, 72 Chief Scientific Officer & SVP-Research, Biocept, Inc. The company said that Beacon Laboratory Benefit Solutions Inc, or BeaconLBS, connects physicians and their patients to its Labs-of-Choice network, which are preferred, high-quality laboratories that now including Biocept. “The launch of our liquid biopsy kit strategy has been a priority for Biocept, and we are excited to now have the ability to leverage the value of our patents as we enable laboratories around the world to utilize our proprietary Target Selector technologies,” said Michael Nall, president and CEO of Biocept in a press release. has a market cap of US$18m, and reported total annual CEO compensation of US$440k for the year to December 2018. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call August 12, 2019 4:30 PM ET Company Participants. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall and CFO & SVP of Operations Tim Kennedy joined Christine Corrado at Proactive's New York studio following their attendance at the H. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN Network LOS ANGELES, CA / ACCESSWIRE / March 18, 2020 / StockNewsNow. Wainwright Global. Nall will present a corporate. 27% to trade at $2. SAN DIEGO, April 28, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, April 28, 2020 /PRNewswire/ -- Biocept, Inc. Market Data by Xignite and BATS BZX Real-Time Price. Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020 PR Newswire (US) - 4/29/2020 8:05:00 AM: Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/29/2020 7:56:14 AM. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Why Biocept, Inc. Tim Kennedy - SVP. The conference call can be accessed by dialing (855) 656-0927 for domestic. 's (NASDAQ:BIOC) CEO Pay Matters To You Mike Nall became the CEO of Biocept, Inc. In this SNNLive Video Interview, our host spoke with Mike Nall, CEO of Biocept, Inc. Biocept President and CEO Michael Nall stated, "We are very pleased to make our Target Selector™ platform available for testing CSF, as a more rapid identification of molecular alterations in brain metastases can aid physicians in choosing the best treatment options for their patients with breast or lung cancer. SAN DIEGO, Nov. We are working on Hematology Analyzers, Chemistry Analyzers, Clinical Chemistry Kits, Hematology Reagents, Plate Readers, Washers, H. Biocept Appoints Cory J. At the time of writing our data says that Biocept, Inc. SAN DIEGO, Feb. Biocept Enters Into Laboratory Services Agreement With California-Based Independent Physician Association PRESS RELEASES. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN Network LOS ANGELES, CA / ACCESSWIRE / March 18, 2020 / StockNewsNow. (BIOC) , a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. When it comes to the technical analysis of BIOC stock, there are more than several important indicators on the company’s success in the market, one of those being the Relative Strength Indicator (RSI), which can show, just as Stochastic measures, what is going on with the value of the stock beneath the data. Biocept, Inc. Here’s what’s happening: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas! BIOC […]. com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Mike Nall, CEO of Biocept, Inc. Corporate Governance Biocept, Inc. In 2019, three Biocept executives received on average a compensation package of $829. He is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. com Facebook View on Facebook LinkedIn View on LinkedIn Twitter View on Twitter Contact Email [email protected] All Company Executives Biocept Inc. Biocept with ticker code (BIOC) now have 1 analysts covering the stock. Biocept, Inc. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call August 12, 2019 4:30 PM ET Company Participants. At the time of writing, our data says that Biocept, Inc. Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. Industry, sector and description for Biocept. Common Stock (BIOC) Biocept to Present at the 22nd Annual BIO CEO & Investor Conference Biocept, Inc. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. , Suite 150 San Diego, CA 92121 Customer Service: 888. (NASDAQ:BIOC) in 2013. David Hale is 70, he's been the Non-Executive Chairman of the Board of Biocept since 2014. The company’s cancer assays provide an information to oncologists and other physicians that enable them to select personalized treatment. stock and Diagnostics & Research market discussion, news, and analysis from Canada's largest community of active investors Stockhouse. Biocept also began the year aiming to improve the collections and billing system with a view to making it more efficient and effective. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept to Begin COVID-19 Testing. Nall, the company's CEO, said in a statement. (NASDAQ: Selector™ assays to help physicians better understand treatment options for their patients with breast cancer," said Biocept's President and CEO Michael Nall. A free inside look at company reviews and salaries posted anonymously by employees. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. At BioSig Technologies, we are dedicated to developing new ways to help patients and physicians. Securities products and services offered to self-directed investors through ST Invest, LLC. 2 million in cash as of March 31, 2018. B Units,and other labs equipments. htm Exhibit 99. Biocept (BIOC) reported a Quarter December 2019 loss of $0. 25, 2016 /PRNewswire/ -- Biocept, Inc. 5810 Nancy Ridge Dr. has a market cap of US$18m, and reported total annual CEO compensation of US$440k for the year to December 2018. Biocept, Inc. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. Biocept was founded in 1997, and plans to list on the Nasdaq market under the symbol BIOC. com Facebook View on Facebook LinkedIn View on LinkedIn Twitter View on Twitter Contact Email [email protected] Here’s what’s happening: Stop …. Nall issued letter to stockholders. Mike Nall became the CEO of Biocept, Inc. Biocept to Begin COVID-19 Testing. Nall will present a corporate overview at the 22nd Annual BIO CEO & Investor Conference on Monday. About Biocept. Michael Nall, Biocept’s President and CEO, remarked: The promise of liquid biopsy is beginning to be realized broadly, given the ability to use a simple blood sample to access the same information found with an invasive tissue biopsy. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript biopharmaceutical companies and clinical trial support and specific oncogenic alterations. 76% from its latest closing price when compared to the 1-year high value of $2. Chief Executive Officer and President Biocept, Inc. They offer tests for many kinds of cancer, including breast, colon, prostate, and lung. 4, 2020 /PRNewswire/ -- Biocept, Inc. The company had less than $2. Biodesix Partners with Streck to Support In Vitro Diagnostic (IVD) Strategy. 67 per share on Oct 24 for a total of $421334. 78% of Nall's compensation, or $617. 's (NASDAQ:BIOC) CEO Pay Matters To You Mike Nall became the CEO of Biocept, Inc. 46,233 people own Biocept on Robinhood on May 6, 2020. Member FINRA / SIPC. "I'm exceptionally proud of our strong operational performance throughout 2019 and into 2020," Biocept CEO Mike Nall has said. SAN DIEGO, Nov. , the largest health insurer in Iowa and South Dakota. The graphic below shows how CEO compensation at Biocept has changed from year to year. Biocept Inc (NASDAQ: BIOC) is making a run for the top in the market this morning, trading on gains of around 15%. The one-year performance of Biocept Inc. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript Seeking Alpha Nov 13, 2019 Biocept EPS beats by $0. Hale, 70 Non-Executive Chairman. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Mike Nall has been the CEO of Biocept, Inc. stock is -60. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference News provided by. com! E-mail Address. Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. However, sales failed to impress the street. 3% to 58 cents at the time of publication Monday. To access Person ’s phone and email just run the installation wizard and get the ZoomInfo Community Edition. SAN DIEGO, April 28, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, April 28, 2020 /PRNewswire/ -- Biocept, Inc. Join to Connect. "Our ability to expand internationally is a testament to the scalability of our platform as we deliver liquid biopsy testing to the medical community worldwide," Biocept President and CEO Michael Nall said in a statement. Mike Nall has been the CEO of Biocept, Inc. Biocept will begin accepting physician-ordered testing requests for patients to receive the COVID-19 molecular diagnostic test developed by Carlsbad’s ThermoFisher starting April 15. 5810 Nancy Ridge Dr. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive's Steve Darling with news the company can start selling their Target Selector molecula. 4, 2020 SAN DIEGO, Feb. Michael Nall - President and CEO. Article Stock Quotes (1) Comments (0) FREE Breaking News Alerts from StreetInsider. Michael Nall is the CEO of Biocept, a company based in San Diego which has gone about as far as any organization in commercializing these non-invasive tests. SAN DIEGO, Feb. Here’s what’s happening: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas! BIOC […]. your username. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday. , a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued P - Biocept, Inc. : Scientist or Sr. Biocept (BIOC) Technical Analysis. Why Biocept, Inc. 14/1/2020: 07:05: PRNUS: Biocept Announces Validation and Availability of its Liquid. "We believe that the. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference PR Newswire +8. Biocept, Inc. SAN DIEGO, May 12, 2016 /PRNewswire/ -- Biocept, Inc. 25 at the time of publication Monday. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN Network. streetinsider. Nall, the company's CEO, said in a statement. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript biopharmaceutical companies and clinical trial support and specific oncogenic alterations. , a Chairman at Recros Medica, Inc. Description: Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with. Hale was appointed Executive Chairman of Biocept in March 2011. 2/20/2019 8:06:06 AM Biocept President And CEO Michael Nall Issues Letter To Stockholders 2/8/2019 8:52:14 AM Biocept Reports Pricing Of $7. Bruce A has 12 jobs listed on their profile. A free inside look at company reviews and salaries posted anonymously by employees. Biocept, Inc. Biocept Reports 2019 Fourth Quarter and Full Year Financial Results PR Newswire (US) - 3/25/2020 4:05:00 PM: Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020 PR Newswire (US) - 3/18/2020 8:05:00 AM: Statement of Ownership (sc 13g) Edgar (US Regulatory) - 3/13/2020 4:11:09 PM. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information. Press Release; load more. Michael Goldberg has served as a member of our board of directors since November 2011. 8225 Email: [email protected] Nall has issued the following letter to stockholders:. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. "Our new dual sample kit offers researchers and assay developers efficiencies and cost savings, including. Biocept shares were jumping 63. (Shutterstock) SAN DIEGO, CA — A San Diego-based molecular. LOS ANGELES, CA / ACCESSWIRE / March 18, 2020 / StockNewsNow. Feb 04, 2020, 08:05 ET. 36 closing price. 3% to 58 cents at the time of publication Monday. BIOC 19/04/2020 00:57:39 1-888-992-3836 Free Membership Login Monitor. Here’s what’s happening: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas! BIOC […]. Kevin McCabe - LHA, IR. SAN DIEGO, Feb. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to. 4, 2020 /PRNewswire/ -- Biocept, Inc. 29 and move down -593. Biocept, Inc. Biocept To Present At The 22nd Annual BIO CEO & Investor Conference. Ask a question. Run by investors for investors Proactive Investors is a Leading source of in-depth comment, analysis, financial news, press releases and share price data on small to large capitalised companies on the Australian Stock Exchange, Toronto Stock Exchange. has a market cap of US$18m, and reported total annual CEO compensation of US$440k for the year to December 2018. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to. Biocept was founded in 1997, and plans to list on the Nasdaq market under the symbol BIOC. Press Release; load more. SAN DIEGO, April 28, 2020 /PRNewswire/ -- Biocept, Inc. The company said that Beacon Laboratory Benefit Solutions Inc, or BeaconLBS, connects physicians and their patients to its Labs-of-Choice network, which are preferred, high-quality laboratories that now including Biocept. Nall says, along these lines, Biocept was recently awarded a patent. Biocept, Inc. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference Published. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to. CA, an investment chat community for Canada's small cap markets. Please wait while we load your information from QuoteMedia. Revenue grew 107. Company Website. 5810 Nancy Ridge Drive San Diego, CA 92121 (858) 320-8200 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to:. Biocept, Inc. Their Lead411 profile is categorized under the Biotech/drugs industry. Mar 26, 2020 12:05 PM UTC Biocept's President and CEO. Its revenue is up 2. Nall issued letter to stockholders. Biocept's revenue is the ranked 7th among it's top 10 competitors. At the time of writing, our data says that Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. NasdaqCM:BIOC CEO Compensation, April 10th 2019 Is Biocept, Inc. Real-time discussion about Biocept, Inc. (BIOC) is based in the USA and it represents one of the well-known company operating with Healthcare sector. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference PR Newswire - Tue Feb 4, 7:05AM CST CMTX - Tue Feb 4, 7:05AM CST Biocept, Inc. San Diego Life Sciences Roundup: Evoke, Halozyme, Biocept, and More. 53M shares in trading volumes in the last trading session, way higher than the average trading volume of 15. SAN DIEGO, Feb. Here’s what’s happening: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas! BIOC […]. SAN DIEGO, Aug. Guidelines. Late last week, just before the holiday weekend, the diagnostics company said that it would begin COVID-19 testing. 3 Biocept reviews in San Diego, CA. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. is Margaret Faye Wilson, 81, who is the Lead Independent Director. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. Biocept to Begin COVID-19 Testing. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Entering into the global market with a scaled offering for liquid biopsy is the first step toward growing from an exclusive CLIA lab business to a technology and products company. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference PR Newswire +8. SAN DIEGO, Jan. 4, 2020 at 8:05 a. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (presently. 8 on InfoTrie's scale. 5 Mln Public Offering. "The healthcare community understands the importance of tracking and monitoring biomarker status in order to successfully treat cancer patients," said Mike Nall, CEO of Biocept. , a Chairman at Recros Medica, Inc. Nall will present a corporate. Industry, sector and description for Biocept. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. "We are pleased to reach an agreement with a second large California-based IPA, this one in the southern part of the state, to provide liquid biopsy services for patients diagnosed with cancer," said Michael Nall, Biocept's President and CEO. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. Michael Nall, CEO & President, Director at Biocept (BIOC), is currently unranked, see this insider's latest transactions. View the real-time BIOC price chart on Robinhood and decide if you want to buy or sell commission-free. Specialize in assay development. Margaret Faye Wilson, 81 Lead Independent Director, Biocept, Inc. Biocept will begin accepting physician-ordered testing requests for patients to receive the COVID-19 molecular diagnostic test developed by Carlsbad’s ThermoFisher starting April 15. Biocept's revenue is the ranked 7th among it's top 10 competitors. "I am very thankful to our laboratory team for stepping up and quickly validating COVID-19 testing, in addition to the vital work we do each day for patients diagnosed with cancer," Biocept CEO Mike Nall said in a statement. 6 million each quarter. At the time of writing our data says that Biocept, Inc. LOS ANGELES, CA / ACCESSWIRE / March 18, 2020 / StockNewsNow. CEO Michael Nall said following this announcement, “We believe that our pathology partnership platform offers urologists and uropathologists a unique solution to evaluate and treat their patients diagnosed with prostate cancer, which further distinguishes Biocept from other commercial liquid biopsy services. "We are extremely pleased to be working with Biocept to harness the data generated by its Target Selector testing platform," Sundeep Bhan, Co-founder and CEO of Prognos said. 76% Jan-14-20 08:05AM Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid PR Newswire +14. Biocept, Inc. This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. Daily Earnings Calls 16 views. Michael W Nall is President/CEO at Biocept Inc. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript Seeking Alpha Nov 13, 2019 Biocept EPS beats by $0. The best long-term & short-term Biocept share price prognosis for 2020. Biocept, Inc. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (presently Decipher Biosciences), PLUS Diagnostics (presently Inform Diagnostics) and Genoptix. com - 14 - Shares of Biocept Inc. Biocept will begin accepting physician-ordered testing requests for patients to receive the COVID-19 molecular diagnostic test developed by Carlsbad’s ThermoFisher starting April 15. Real-time Insider Trading Stock Screener. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall and CFO & SVP of Operations Tim Kennedy joined Christine Corrado at Proactive's New York studio following their attendance at the H. Griffin Regional President (Americas) HILL INTERNATIONAL INC: Michael W. (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable. About Biocept Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. At the time of writing our data says that Biocept, Inc. Biocept understands that many of our clients have taken precautionary measures to help prevent the spread of the virus and some maybe delaying or rescheduling patient appointments. "I'm exceptionally proud of our strong operational performance throughout 2019 and into 2020," Biocept CEO Mike Nall has said. 25% of gains with the last five trading sessions. Monitor SEC Form 4 Insider Trading Filings for Insider Buying and Selling. The past year saw the firm’s share price begin trading at above $20 per share and close the year trading below $1, an over 95% decline in the price. Bigelow was the editor of. The one-year performance of Biocept Inc. Here's what's going on: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!. The Wall Street Transcript is a completely unique resource for investors and business researchers. (NASDAQ: BIOC), is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. Feb 9 (Reuters) - Biocept Inc * Biocept’s CEO issues letter to stockholders * Biocept- Later in year, plan to initiate commercial pilot program for hospital-based pathologists to interpret. Specialize in assay development. "We are extremely pleased to be working with Biocept to harness the data generated by its Target Selector testing platform," Sundeep Bhan, Co-founder and CEO of Prognos said. "We are pleased to welcome Dr. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. 2/20/2019 8:06:06 AM Biocept President And CEO Michael Nall Issues Letter To Stockholders 2/8/2019 8:52:14 AM Biocept Reports Pricing Of $7. com! E-mail Address. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. 5M; in Q2 2019, it was $1. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. April 29, 2020 Comments Off on fuboTV (OTC: FBNK) CEO David Gandler Featured by Wedbush Securities Managing Director of Digital Media Equity Research Michael Pachter in Public Company Spotlight ImagineAR (OTC: IPNFF) Signs Five Year $300,000USD Licensing Agreement with SlapItOn to Provide Augmented Reality for Athletes and Celebrities to Engage. Michael Nall, Biocept’s President and CEO, remarked: The promise of liquid biopsy is beginning to be realized broadly, given the ability to use a simple blood sample to access the same information found with an invasive tissue biopsy. Biocept also began the year aiming to improve the collections and billing system with a view to making it more efficient and effective. (This number is for the twelve months until December 2018). The following slide deck was published by Biocept, Inc. Nall President and Chief Executive Officer About Biocept Biocept, Inc. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive's Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving. The details. ET on Seeking Alpha Biocept (BIOC) Receives a Buy from Maxim Group. "We are extremely pleased to be working with Biocept to harness the data generated by its Target Selector testing platform," Sundeep Bhan, Co-founder and CEO of Prognos said. Biocept, Inc. Biocept will begin accepting physician-ordered testing requests for patients to receive the COVID-19 molecular diagnostic test developed by Carlsbad’s ThermoFisher starting April 15. Michael Nall President and CEO at Biocept Orange County, California Area 500+ connections. Biocept has their own liquid biopsy platform known as Target Selector TM which can analyze tumor markers. Dunn has served as Biocept's Vice President of Commercial Operations since October 2018. SAN DIEGO, April 28, 2020 /PRNewswire/ -- Biocept, Inc. A free inside look at company reviews and salaries posted anonymously by employees. 8 on InfoTrie's scale. "The entire team is united behind Cory's sales and marketing leadership and we look forward to providing updates on our commercial. BioCryst shares were gaining 21. The graphic below shows how CEO compensation at Biocept has changed from year to year. Salaries, reviews and more - all posted by employees working at Biocept. In this SNNLive Video Interview, our host spoke with Mike Nall, CEO of Biocept, Inc. The MarketWatch News Department was not involved in the creation of this content. Biocept will begin accepting physician-ordered testing requests for patients to receive the COVID-19 molecular diagnostic test developed by Carlsbad's ThermoFisher starting April 15. 7729 Company Operator: 858. Kevin McCabe - LHA, IR. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the diagnosis and. Biocept's President and CEO. Welcome! Log into your account. Biocept, Inc. Mike Nall became the CEO of Biocept, Inc. Eastern time to discuss these results and answer questions. About Biocept Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Report this profile; Activity. Biocept said today it will partner with Shilpa Gupta, Ph. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript: 03/25/2020 04:07 PM EDT: SeekingAlpha : Biocept EPS misses by $0. Biocept shares were jumping 63. Nall announced that to spearhead the improvements would be Tim Kennedy, the company’s operations vice president and chief financial officer, who joined the company a little over six months ago. Nall, the company's CEO, said in a statement. Biocept President and CEO Michael Nall stated, "We are very pleased to make our Target Selector™ platform available for testing CSF, as a more rapid identification of molecular alterations in brain metastases can aid physicians in choosing the best treatment options for their patients with breast or lung cancer. (NASDAQ:BIOC) Q4 2018 Results Earnings Conference Call March 28, 2019 4:30 PM ET Company Participants. has inked a deal with Scripps Health making Biocept the system’s preferred provider for cancer-related liquid biopsy tests. , a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with. Hale, 70 Non-Executive Chairman, Biocept, Inc. Mike Nall has been the CEO of Biocept, Inc. Tim Kennedy - SVP. Find CEO in Medical Testing & Clinical Laboratories contacts. Foundation Medicine, The Molecular Information Company, is connecting physicians and their patients to the latest cancer treatment approaches and making precision medicine a reality for thousands. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Kevin McCabe - LHA, IR. Biocept, Inc. The letter stated that Biocept team is looking forward to 2017, as they work to advance their position as a commercial. "We are extremely pleased to be working with Biocept to harness the data generated by its Target Selector testing platform," Sundeep Bhan, Co-founder and CEO of Prognos said. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN Network - Yahoo Finance. Biocept (BIOC) Releases CEO Letter to Stockholders Article Related Press Releases ( 1 ) Stock Quotes (1) Comments (0) FREE Breaking News Alerts from StreetInsider. Biocept, Inc. 0 on Oct 28. Biocept shares were jumping 63. Nall has issued the following letter to stockholders:. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE Mark geographies. Specialize in assay development. Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020 - StreetInsider. Biocept needed to do something to raise cash, though -- and fast. , according to the company's website (see here: www. com Phone Number 858-320-8200 Biocept, an emerging biotechnology leader in cell separation technology, is developing a new, powerful class of diagnostic assays for personalized medicine in early detection, diagnosis and. When it comes to the technical analysis of BIOC stock, there are more than several important indicators on the company’s success in the market, one of those being the Relative Strength Indicator (RSI), which can show, just as Stochastic measures, what is going on with the value of the stock beneath the data. Nall will present a corporate overview at the 22nd Annual BIO CEO & Investor Conference on Monday. Nall has issued the following letter to stockholders:. 8225 Email: [email protected] 75% at the open. Biocept Reports 2019 Fourth Quarter and Full Year Financial Results PR Newswire (US) - 3/25/2020 4:05:00 PM: Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020 PR Newswire (US) - 3/18/2020 8:05:00 AM: Statement of Ownership (sc 13g) Edgar (US Regulatory) - 3/13/2020 4:11:09 PM. SAN DIEGO, Feb. SAN DIEGO, Nov. A free inside look at company reviews and salaries posted anonymously by employees. Industry, sector and description for Biocept. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Biocept against related stocks people have also bought. On March 28, 2017, Biocept, Inc. 's (NASDAQ:BIOC) CEO Pay Matters To You Mike Nall became the CEO of Biocept, Inc. Biocept's Chairman of the Board is David F. is a commercial-stage cancer diagnostics company. The MarketWatch News Department was not involved in the creation of this content. com email addresses and possibly Michael Nall's email. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Biocept, Inc. The patent covers the use of antibody cocktails to capture rare cells such as circulating tumor cells from any biological sample. 11, 2020 12:11 PM ET. (NASDAQ: BIOC) soared 56. Feb 04, 2020, 08:05 ET. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript. Michael Nall, President and CEO of Biocept, commented, "We believe the findings from this study are valuable as they help in our understanding of ovarian cancer metastasis, and how to improve. NAPOLITAN RAYMOND S JR (Executive Vice President) sold 8,000 shares at $52. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE Mark geographies. SAN DIEGO, Jan. Founder of Molecular Biosystems, Inc. Biocept, Inc. Hale, 70 Non-Executive Chairman, Biocept, Inc. 53M shares by far recorded in the movement of Biocept (BIOC). Chief Executive Officer and President Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript 8:15PM ET 3/25/2020 Seeking Alpha Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. Address: 5810 Nancy Ridge Drive, Suite 150, San Diego, CA, USA, 92121: Telephone: +1 858 320-8200: Website: https://www. 2019-05-20 marketwatch. BIOC stock has a five-year performance of -99. However, sales failed to impress the street. The Wall Street Transcript is a completely unique resource for investors and business researchers. Biocept Appoints Michael Nall as CEO September 10, 2013 02:36 PM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )--Biocept, Inc. Dunn has served as Biocept's Vice President of Commercial Operations since October 2018. A free inside look at Biocept salary trends based on 5 salaries wages for 4 jobs at Biocept. (NASDAQ: BIOC), a leading commercial. The target price ranges between 1 and 1 and has a mean target at 1. Specifically, in Q4 2019's revenue was $1. This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio. Prior to joining Biocept, she held multiple leadership positions at life sciences companies. Biocept, Inc. Biocept Appoints Michael Nall as CEO SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Press Release; load more. CFO Search Report, a. 1 Wall Street analysts have issued ratings and price targets for Biocept in the last 12 months. 5810 Nancy Ridge Dr. Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. This is the Biocept company profile. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (presently. Biocept Inc (NASDAQ:BIOC), a commercial developer of liquid biopsy tests, announced Tuesday that its Target Selector molecular assay EGFR kit has earned a CE-IVD (in-vitro diagnostic) mark from European regulators. CURRENT PRICE. BIOC, a molecular diagnostics company commercializing and developing blood-based biomarkers to improve. Biocept will begin accepting physician-ordered testing requests for patients to receive the COVID-19 molecular diagnostic test developed by Carlsbad’s ThermoFisher starting April 15. Biocept Inc (NASDAQ: BIOC) is having a rough start to the trading session, down about 2. via Skype, and they discuss. “Results of this study could open new market opportunities for Biocept,” Michael W. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W. Mar 26, 2020 12:05 PM UTC Biocept's President and CEO. If you have patients who need laboratory testing by Biocept and who may not be able to come to your office for a blood draw, please contact our customer. 76% from its latest closing price when compared to the 1-year high value of $2. McKim & Creed, Inc. CEO Michael Nall said following this announcement, “We believe that our pathology partnership platform offers urologists and uropathologists a unique solution to evaluate and treat their patients diagnosed with prostate cancer, which further distinguishes Biocept from other commercial liquid biopsy services. Keep tabs on your portfolio, search for stocks, commodities, or mutual funds with screeners, customizable chart indicators and technical analysis. Wilson is the chair of Biocept's audit committee. Linda Macander Executive Assistant to CEO at Biocept Greater San Diego Area Biotechnology. "We are pleased to welcome Dr. About Biocept. We are working on Hematology Analyzers, Chemistry Analyzers, Clinical Chemistry Kits, Hematology Reagents, Plate Readers, Washers, H. Biocept earned a media sentiment score of 2. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. From January 2005 to May 2011, Mr. Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (presently. This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. ET on Seeking Alpha Biocept (BIOC) Receives a Buy from Maxim Group. Biocept Inc (NASDAQ: BIOC) Biocept is having an. 6 million each quarter. 5K, was in option. Biocept Reports 2019 Fourth Quarter and Full Year Financial Results PR Newswire (US) - 3/25/2020 4:05:00 PM: Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020 PR Newswire (US) - 3/18/2020 8:05:00 AM: Statement of Ownership (sc 13g) Edgar (US Regulatory) - 3/13/2020 4:11:09 PM. Then we'll look at a snap shot of the business growth. Hale served as Hybritech’s president, COO, and CEO. 67 per share on Oct 24 for a total of $421334. 7729 Company Operator: 858. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The oldest executive at Biocept, Inc. SAN DIEGO, April 28, 2020 /PRNewswire/ -- Biocept, Inc. President and Chief Executive Officer. 's ISS Governance QualityScore as of N/A is N/A. Biocept Inc is based in San Diego, CA. Nall has issued the following letter to stockholders:. Dunn brings 20 years of commercial experience in the life science industry to Biocept, and served as Biocept's Vice President of Marketing since 2018. Nall is the President and Chief Executive Officer of Biocept, Inc. (the “ Compan y”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain purchasers identified on the signature pages thereto (the “ Purchasers ”), pursuant to which the Company will offer to the Purchasers, in a registered direct offering, an aggregate of 4,320,000 shares (the “ Shares ”) of common stock, par. The recent performance of Biocept (NASDAQ:BIOC) stock in the market spoke loud and clear to investors as BIOC saw more than 15. (NASDAQ:BIOC) in 2013. Biocept, Inc. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE Mark geographies. The analyst consensus points to a rating of ‘Buy’. in conjunction with this event. The best questions are directly relevant to BIOCEPT. "The expansion of our intellectual property continues the global validation of our technology and further positions Biocept as a provider of cutting-edge approaches for the detection of rare genetic events using blood and other fluids," stated Michael Nall, Biocept's president and CEO. On Monday, shares of Biocept, Inc.